Antibody Industry Trends

The nucleocapsid of a virus, which consists of the capsid enclosing the viral nucleic acid, can be a target for antibody therapies. When a virus infects a host, its nucleocapsid becomes exposed to the immune system, triggering the production of antibodies specific to proteins present on the nucleocapsid's surface, preventing the virus from entering host cells, disrupting its replication cycle, or marking it for destruction by other components of the immune system.

In the realm of combating bacterial infections and antimicrobial resistance, antibodies are beginning to stand out as a therapy with innovative strategies and engineering methods continually being published. This month’s trend will focus on the developments in ‘antibiotic antibodies’, antibody-antibiotic conjugates, and antibody antimicrobials, which are particularly important for immunocompromised patients.

Toxins are substances produced by living organisms, such as bacteria, fungi, plants, and animals, that are harmful to other organisms. Antibodies play a crucial role in immune responses for the body's defense against toxin intoxication, in addition to being invaluable tools for both diagnostic and therapeutic applications.

Agonistic antibodies bind to specific receptors on cells and mimic the action of the natural ligand of that receptor, thereby activating signaling pathways and eliciting cellular responses. Unlike traditional antibodies, which are often used to block or neutralize the activity of their target molecules (acting as antagonists), antibody agonists actively stimulate a biological response. Recently, more studies are delving into the mechanisms and therapeutic potential of these antibody agonists.

Antibody combination therapies involve the use of two or more antibodies together as a treatment strategy to enhance the therapeutic effect against diseases, such as cancer or infectious diseases. This approach aims to target different epitopes or antigens simultaneously, increasing the efficacy of the treatment by overcoming resistance mechanisms, reducing the likelihood of disease escape, and providing a broader range of action.

Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow, which can cause bone damage, anemia, kidney dysfunction, and weakened immunity. Despite being incurable, advances in antibody therapies have shown significant progress in the management of the disease, highlighting the ongoing efforts in the development of more effective treatments.

Entering into the new year, the popularity of antibody-drug conjugates (ADCs) in the biopharma industry shows no signs of slowing down. In 2023, there were a record number of licensing partnerships in the ADC space, particularly Merck’s $22 billion deal with Daiichi Sankyo, Inc.

The antibody industry has experienced significant growth and transformation in 2023, driven by research and technological advancements, a focus on collaboration, and the impact of the COVID-19 pandemic.

Research into treatments for Alzheimer's disease (AD) has reached impressive milestones this year.

The last few decades have witnessed an acceleration in the discovery and development of therapeutic antibodies.

Respiratory syncytial virus (RSV) has recently gained much attention due to the approval of several drugs this year.On May 3, 2023, the U.S. Food and Drug Administration (FDA) authorized Arexvy, the first RSV vaccine for use in the United States.